DCT

1:21-cv-01186

Endo Ventures Ltd v. Nevakar Injectables Inc

Log In

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:21-cv-01186, D. Del., 04/21/2023
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendant is a Delaware corporation.
  • Core Dispute: Plaintiff alleges that Defendant’s ready-to-administer norepinephrine bitartrate intravenous solutions infringe five patents related to stable, antioxidant-free pharmaceutical compositions and associated methods.
  • Technical Context: The technology concerns ready-to-use formulations of norepinephrine, a critical vasopressor drug used in hospital settings to treat acute hypotension, designed to improve stability and eliminate the need for bedside dilution.
  • Key Procedural History: The complaint alleges that a former exclusive licensee of four of the patents-in-suit sent a letter to Defendant on February 19, 2021, providing notice of those patents before the commercial launch of the accused products. This allegation of pre-suit knowledge forms the basis for Plaintiff's claims of willful infringement for those patents.

Case Timeline

Date Event
2017-01-30 Earliest Priority Date for all Patents-in-Suit
2019-09-24 U.S. Patent No. 10,420,735 Issues
2019-11-12 U.S. Patent No. 10,471,026 Issues
2020-02-25 U.S. Patent No. 10,568,850 Issues
2020-03-16 Defendant Files New Drug Application (NDA) for Accused Products
2020-05-12 U.S. Patent No. 10,646,458 Issues
2021-01-15 FDA Approves Defendant's NDA for Accused Products
2021-02-19 Former Licensee Allegedly Notifies Defendant of Four Patents-in-Suit
2021-09-01 Alleged Start Date for Delivery of Accused Products
2021-09-23 Defendant Announces FDA Approval and Commercial Launch of Accused Products
2023-03-14 U.S. Patent No. 11,602,508 Issues
2023-04-21 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,602,508 - “Norepinephrine Compositions and Methods Therefor”

  • Patent Identification: U.S. Patent No. 11,602,508, titled “Norepinephrine Compositions and Methods Therefor,” issued on March 14, 2023.

The Invention Explained

  • Problem Addressed: The patent’s background section describes problems with existing norepinephrine products, which are typically supplied as concentrates requiring dilution before administration. This process introduces risks of microbial contamination and dosing errors, and the diluted formulations lack long-term storage stability. Furthermore, some existing formulations contain sulfites as antioxidants, which can cause severe allergic reactions in susceptible individuals (Compl. ¶14; ’508 Patent, col. 2:3-22).
  • The Patented Solution: The patent describes a ready-to-administer, sterile, aqueous norepinephrine composition that is stable without the need for conventional antioxidants. Stability is achieved by formulating the composition within a specific acidic pH range (3.7 to 4.3) and including a chelating agent, which together are described as minimizing both degradation and isomerization of the active R-isomer of norepinephrine to the less-active S-isomer over time (’508 Patent, col. 4:15-44, Abstract).
  • Technical Importance: This approach provides a ready-to-use product that can enhance patient safety in critical care settings by eliminating the need for bedside dilution, thereby reducing the risk of calculation errors and contamination while also avoiding potentially allergenic sulfite antioxidants (’508 Patent, col. 6:1-6).

Key Claims at a Glance

  • The complaint asserts independent claim 1 (Compl. ¶23).
  • Claim 1 of the ’508 patent recites the following essential elements:
    • A ready-to-administer norepinephrine composition;
    • Comprising an aqueous solution with a pH between 3.7 and 4.3;
    • The solution contains norepinephrine at a concentration between 10 µg/ml and 100 µg/ml, initially comprising at least 95% R-isomer;
    • The solution contains a chelating agent comprising a tartrate bicarboxylic acid at a concentration between 10 µg/ml and 100 µg/ml;
    • The solution contains a tonicity agent;
    • The composition is substantially free of antioxidants; and
    • After three months of storage at 25°C/60% relative humidity, the norepinephrine comprises at least 90% R-isomer (Compl. ¶24).
  • The complaint does not explicitly reserve the right to assert dependent claims.

U.S. Patent No. 10,420,735 - “Norepinephrine Compositions and Methods Therefor”

  • Patent Identification: U.S. Patent No. 10,420,735, titled “Norepinephrine Compositions and Methods Therefor,” issued on September 24, 2019.

The Invention Explained

  • Problem Addressed: The patent addresses the same technical problems as the ’508 Patent: the instability, risk of error, and potential for allergic reactions associated with conventional, concentrated norepinephrine formulations that require dilution and contain sulfite antioxidants (’735 Patent, col. 2:2-20).
  • The Patented Solution: The patent claims a method of treating hypotension by administering a ready-to-administer norepinephrine composition. The method specifies a two-phase dosing regimen: a higher initial dose (8-12 µg/min) followed by a lower maintenance dose (2-4 µg/min). The composition used in this method is defined by the same stabilizing features as in the ’508 patent, including a specific pH range, the presence of a chelating agent, and the absence of antioxidants (’735 Patent, col. 4:26-44, col. 19:46-49, Table 21).
  • Technical Importance: By claiming a specific clinical method of use for a stabilized, ready-to-administer product, the patent covers the practical application of the formulation technology, standardizing a dosing protocol for a safer and more convenient drug product (’735 Patent, col. 19:46-49, Table 21).

Key Claims at a Glance

  • The complaint asserts independent claim 1 (Compl. ¶37).
  • Claim 1 of the ’735 patent recites the following essential elements:
    • A method of treating hypotension;
    • Comprising administering a ready-to-administer norepinephrine composition at an initial dose per minute, followed by a maintenance dose per minute;
    • The initial dose is between 8 and 12 µg/min, and the maintenance dose is between 2 and 4 µg/min;
    • The composition comprises norepinephrine at a concentration of 10-100 µg/ml in an aqueous acidic solution with a pH of 3.7-4.3;
    • The solution further comprises a chelating agent (1-100 µg/ml) and a tonicity agent;
    • The composition is substantially free of antioxidants; and
    • The composition is stable, maintaining at least 90% R-isomer after three months of storage (Compl. ¶38).
  • The complaint does not explicitly reserve the right to assert dependent claims.

U.S. Patent No. 10,471,026 - “Norepinephrine Compositions and Methods Therefor”

  • Patent Identification: U.S. Patent No. 10,471,026, titled “Norepinephrine Compositions and Methods Therefor,” issued November 12, 2019 (Compl. ¶10).
  • Technology Synopsis: This patent is directed to a method of controlling the content of the less-active S-isomer in a ready-to-administer norepinephrine composition. The claimed method involves admixing an R-isomer of norepinephrine, a chelating agent, and a tonicity agent into an aqueous acidic solution having a pH between 3.7 and 4.3, with the final composition being substantially free of antioxidants, thereby preserving the desired isomeric purity (’026 Patent, Abstract; col. 4:45-50).
  • Asserted Claims: Claim 1 (Compl. ¶54).
  • Accused Features: The complaint alleges that the process Baxter uses to manufacture its norepinephrine products infringes the claimed method (Compl. ¶¶56-57).

U.S. Patent No. 10,568,850 - “Norepinephrine Compositions and Methods Therefor”

  • Patent Identification: U.S. Patent No. 10,568,850, titled “Norepinephrine Compositions and Methods Therefor,” issued February 25, 2020 (Compl. ¶11).
  • Technology Synopsis: This patent claims a sterile, ready-to-administer, packaged norepinephrine composition. The claim requires a primary container filled with the composition, which is itself packaged in a secondary container. The composition within the container is defined by the same key stability-conferring features seen throughout the patent family: specific concentrations, a pH between 3.7 and 4.3, high initial R-isomer purity, stability over time, and a substantial absence of antioxidants (’850 Patent, Abstract; col. 20:50-53).
  • Asserted Claims: Claim 1 (Compl. ¶66).
  • Accused Features: The complaint alleges that the final marketed Baxter Products, which consist of infusion bags (primary container) stored in cartons (secondary container), constitute the claimed packaged composition (Compl. ¶68).

U.S. Patent No. 10,646,458 - “Norepinephrine Compositions and Methods Therefor”

  • Patent Identification: U.S. Patent No. 10,646,458, titled “Norepinephrine Compositions and Methods Therefor,” issued May 12, 2020 (Compl. ¶12).
  • Technology Synopsis: This patent claims a method of preparing a sterile, ready-to-administer norepinephrine composition. The claimed process involves the steps of combining norepinephrine, a chelating agent, and a tonicity agent to form a liquid; adjusting the pH to between 3.7 and 4.3; filling the liquid into a container; and heat sterilizing the filled container to achieve sterility while maintaining the product's stability and isomeric purity (’458 Patent, Abstract; col. 21:49-52).
  • Asserted Claims: Claim 1 (Compl. ¶80).
  • Accused Features: The complaint alleges that Baxter’s manufacturing process for its products, which includes combining ingredients, adjusting pH, filling containers, and heat sterilization, infringes the claimed method (Compl. ¶¶83-84, 87-89).

III. The Accused Instrumentality

  • Product Identification: Baxter's ready-to-administer formulations of norepinephrine bitartrate in 5% dextrose, referred to as the "Baxter Products" (Compl. ¶16).
  • Functionality and Market Context:
    • The accused products are premixed intravenous solutions approved by the FDA "for restoration of blood pressure in adult patients with acute hypotensive states" (Compl. ¶16). They are supplied in 250 mL infusion bags at two strengths: 4 mg (16 µg/mL) and 8 mg (32 µg/mL) (Compl. ¶17). The complaint alleges the products are aqueous solutions containing dextrose and water, have a pH between 3.5-3.9, use the R-isomer of norepinephrine, and do not contain antioxidants (Compl. ¶17).
    • The complaint alleges that Baxter has offered for sale and sold these products in the U.S., including through contracts with major healthcare group purchasing organizations, positioning them as direct competitors to Plaintiff's own products (Compl. ¶¶15, 18-19).
  • Visual Evidence: No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

11,602,508 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A ready-to-administer norepinephrine composition... The Baxter Products are described on their label as ready-to-administer norepinephrine compositions. ¶25 col. 4:15-18
...an aqueous solution having a pH range of between 3.7 and 4.3... The Baxter Products are aqueous solutions with an alleged pH of 3.5-3.9, with an average pH of 3.8. ¶26 col. 4:35-37
...norepinephrine present at a concentration of between 10 µg/ml and 100 µg/ml... The Baxter Products are available in concentrations of 16 µg/ml and 32 µg/ml. ¶29 col. 6:8-12
...wherein the norepinephrine initially comprises at least 95% of R-isomer... The norepinephrine bitartrate used in the Baxter Products is alleged to be the R-isomer. ¶29 col. 4:51-53
...a chelating agent comprising a tartrate bicarboxylic acid, wherein the chelating agent is present at a concentration of between 10 µg/ml and 100 µg/ml... The bitartrate component of the norepinephrine bitartrate active ingredient is alleged to be the claimed chelating agent, present at concentrations of 15.9 µg/mL or 31.8 µg/mL. ¶¶27-28 col. 5:2-8
...a tonicity agent... The Baxter Products contain dextrose, alleged to be a tonicity agent. ¶24 col. 7:6-8
...wherein the ready-to-administer norepinephrine composition is substantially free of antioxidants... The Baxter Products are alleged to not contain any antioxidants. ¶30 col. 4:18-20
...wherein after storage at 25±2° C. and 60±5% relative humidity over at least three months, the norepinephrine comprises at least 90% R-isomer... Plaintiff alleges on information and belief that the Baxter Products are formulated to meet this stability requirement. ¶31 col. 4:20-24

10,420,735 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating hypotension, comprising: administering a ready-to-administer norepinephrine composition... Baxter allegedly instructs physicians to use the Baxter Products to treat hypotension. ¶39 col. 19:46-49
...administering...at an initial dose per minute; administering...at a maintenance dose per minute, wherein the initial dose...is greater than the maintenance dose... Baxter's product label allegedly instructs physicians to initiate a higher dose and titrate to a lower maintenance dose. ¶40 col. 21:1-50, Table 21
...wherein the initial dose per minute is a dose of between 8 and 12 µg/min, and wherein the maintenance dose per minute is a dose of between 2 and 4 µg/min... Baxter's product label allegedly provides dosing instructions that fall within the claimed ranges. ¶40 col. 21:1-50, Table 21
...wherein the norepinephrine composition comprises norepinephrine or a salt thereof at a concentration of between 10 µg/ml and 100 µg/ml in an aqueous acidic solution having a pH range of between 3.7 and 4.3... The Baxter Products are alleged to have concentrations of 16 µg/mL and 32 µg/mL and a pH of 3.5-3.9. ¶41 col. 4:35-40
...wherein the aqueous acidic solution further comprises a chelating agent at a concentration of between 1 µg/ml and 100 µg/ml and a tonicity agent... The bitartrate component is alleged to be the chelating agent (15.9 µg/mL or 31.8 µg/mL). The products allegedly contain dextrose and NaCl as tonicity agents. ¶¶42-43, 45-46 col. 5:1-5
...wherein the norepinephrine composition is substantially free of antioxidants... The Baxter Products are alleged to contain no antioxidants. ¶47 col. 4:40-44
...wherein the norepinephrine...comprises at least about 90% R-isomer of norepinephrine after storage... The complaint alleges that stability testing data for the Baxter Products indicates they meet this limitation. ¶48 col. 4:32-34
  • Identified Points of Contention:
    • Scope Questions: The infringement theory for all asserted patents appears to rely on construing the "bitartrate" counter-ion of the active ingredient (norepinephrine bitartrate) as the claimed "chelating agent." The analysis may turn on whether the term "chelating agent" requires a distinct excipient added to the formulation for that purpose, or if its function being performed by a component of the API salt is sufficient to meet the claim limitation.
    • Technical Questions: For the stability limitations (e.g., "at least 90% R-isomer after storage"), the complaint relies on "information and belief" or inferences from stability data gathered under different conditions than those recited in the claims (Compl. ¶31, ¶48). This raises the question of what factual evidence Plaintiff will be able to produce to demonstrate that the accused products actually meet these specific, quantitative performance requirements under the claimed storage conditions.

V. Key Claim Terms for Construction

  • The Term: "chelating agent"

  • Context and Importance: This term is dispositive for infringement. Plaintiff's theory is that the "bitartrate" component of the active pharmaceutical ingredient (norepinephrine bitartrate) is itself the claimed "chelating agent" (Compl. ¶27, ¶43). The viability of the infringement case may depend entirely on whether this construction is adopted.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specifications explicitly identify "tartrate" as an example of a "bicarboxylic acid," which in turn is listed as a type of chelating agent that can be used in the invention (’508 Patent, col. 5:2-4; ’735 Patent, col. 5:1-4). This language may support Plaintiff's position that the presence of tartrate in any form satisfies the limitation.
    • Evidence for a Narrower Interpretation: The claims recite a composition comprising "norepinephrine or a salt thereof" and, separately, "a chelating agent." This structure could support an argument that the claimed chelating agent must be a component distinct from the norepinephrine salt form itself. The specification also discusses chelating agents like EDTA, which are conventional excipients added separately from the API (’508 Patent, col. 5:48-53; ’735 Patent, col. 5:59-63).

  • The Term: "substantially free of antioxidants"

  • Context and Importance: The patents distinguish the invention from prior art that used sulfite antioxidants. The precise scope of "substantially free" is therefore critical to defining the invention.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification provides a functional definition, stating that compositions are substantially free of antioxidants if they "do not include antioxidants in an amount effective to reduce degradation of total norepinephrine by at least 1% when stored over a period of at least three months at 25° C" (’508 Patent, col. 7:12-16; ’735 Patent, col. 7:26-31). This may allow for trace or incidental amounts of substances with antioxidant properties.
    • Evidence for a Narrower Interpretation: The background sections of the patents strongly criticize the presence of sulfites due to allergic reactions, framing their complete removal as a key objective (’508 Patent, col. 2:17-22; ’735 Patent, col. 2:15-20). This context could support a construction requiring the total absence of any substance added for its antioxidant effect.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement of the method claims of the ’735 patent. The basis for this allegation is that Defendant’s product labeling, marketing, and other instructional materials allegedly instruct and encourage physicians and other healthcare providers to perform the patented method of treating hypotension by administering the accused product using the claimed initial and maintenance dosing regimens (Compl. ¶¶39-40).
  • Willful Infringement: The complaint alleges willful infringement based on pre-suit knowledge. For the ’735, ’026, ’850, and ’458 patents, willfulness is based on Defendant’s alleged knowledge of the patents as of a February 19, 2021 notice letter (Compl. ¶51, ¶63, ¶77, ¶93). For the ’508 patent, which issued after this letter, willfulness is alleged based on knowledge no later than its issue date of March 14, 2023 (Compl. ¶34).

VII. Analyst’s Conclusion: Key Questions for the Case

  • A core issue will be one of claim construction: can the term "chelating agent", which is recited separately from the active ingredient, be construed to read on the "bitartrate" counter-ion that is an integral part of the "norepinephrine bitartrate" salt, or must it be a distinct excipient added to the formulation?
  • A central evidentiary question will be one of technical proof: what evidence will be presented to demonstrate that the accused Baxter products meet the quantitative, long-term stability requirements of the claims (e.g., maintaining at least 90% R-isomer purity after three months of storage), an allegation currently based on inference and "information and belief"?